AzTrials
AzTrials

Respiratory DepressionENDZONENCT02133586

Effects of Sequential Exposure to Nitrogen Dioxide and Ozone in Healthy Adult Human Volunteers.

A study testing Ozone and Nitrogen dioxide in people with Respiratory Depression, run by Environmental Protection Agency (EPA) at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The U.S. Environmental Protection Agency has traditionally examined the effects of single pollutant exposure on human health outcomes; however, to provide a better assessment of pollutant exposure-associated effect on human health the Agency is moving toward a multi-pollutant approach. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Respiratory Depression
What is being tested?
Ozone and Nitrogen dioxide
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
54 participants
Where
1 siteUnited States
Study dates
Jan 2014to Jan 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy men and women between 18 and 40 years of age.
  • Physical conditioning allowing intermittent, moderate exercise for two hours.
  • Ability to complete the exposure exercise regimen without reaching 80% of predicted maximal heart rate.
  • Normal baseline 12-lead baseline EKG or if not normal the EKG must be approved by a study cardiologist.
  • Normal lung function
  • Forced vital capacity (FVC) >75% of that predicted for gender, ethnicity, age, and height (according to National Health and Nutrition Examination Survey [NHANESIII] guidelines).
Show all 9Show fewer
  • Forced expiratory volume in one second (FEV1) > 75% of that predicted for gender, ethnicity, age, and height (according to NHANESIII guidelines).
  • FEV1/FVC ration >75% of predicted values (according to NHANESIII guidelines).
  • Oxygen saturation >96% on room air.

Who cannot join

  • Individuals with a history of acute or chronic cardiovascular disease, chronic respiratory disease, diabetes, rheumatologic disease, or immunodeficiency state.
  • Individuals with a Framingham risk score (Hard Coronary Heard Disease [HCHD] 10-year risk) ≥10.
  • Individuals with asthma or a history of asthma.
  • Individuals who are allergic to chemical vapors or gases.
  • Females who are pregnant, attempting to become pregnant, or breastfeeding.
  • Individuals that are unwilling or unable to stop taking vitamin C or E, or medications that may impact the results of ozone challenge such at least two weeks prior to the study and for the duration of the study. Medications not specifically mentioned here may be reviewed by the investigators prior to an individual's inclusion in the study.
Show all 27Show fewer
  • Individuals who have smoked tobacco during the last five years or those with a history of >5 pack years.
  • Individuals living with a smoker who smokes inside the house.
  • Individuals with a body mass index (BMI) >30 or <18. Body mass index is calculated by dividing the weight in kilograms by the square of the height in meters.
  • Individuals with occupational exposures to high levels of vapors, dust, gases, or fumes on an on-going basis.
  • Individuals with uncontrolled hypertension (≥150 systolic or ≥90 diastolic).
  • Individuals that do not understand or speak English.
  • Individuals that are unable to perform the exercise required for the study.
  • Individuals that are taking beta blocker medications.
  • Individuals with a history of skin allergies to adhesives used in securing EKG electrodes.
  • Individuals with unspecified diseases, conditions, or medications that might influence the responses to the exposures, as judged by the medical staff.
  • Individuals that are unwilling or unable to stop taking over-the-counter pain medications such as aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), or other non-steroidal anti-inflammatory ("NSAID") medications for 48 hours prior to the exposures and post-exposure visits.
  • Individuals that are taking systemic steroids or beta-blocker medications.
  • Individuals with a hemoglobin A1c (HbA1c) level > 6.4%.
  • Temporary Exclusion Criteria
  • Individuals with active seasonal allergies during the time of participation in the study.
  • Individuals suffering from acute respiratory illness within four weeks prior to any of the study exposure series.
  • Individuals that have been exposed to smoke and fumes within 24 hours of any study visit.
  • Individuals that have consumed alcohol within 24 hours of any study visit.
  • Individuals that have engaged in strenuous exercise within 24 hours of any study visit.
  • Individuals that have been exposed to ozone-based home air purifiers within 24 hours of any study visit.
  • Individuals that have been exposed to unvented household combustion sources (gas stoves, lit fireplaces, oil/kerosene heaters) within 48 hours of any study visit.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • E.P.A. Human Studies Facility

    Chapel Hill, North Carolina, 27514

Other trials in United States

About this study

The U.S. Environmental Protection Agency has traditionally examined the effects of single pollutant exposure on human health outcomes; however, to provide a better assessment of pollutant exposure-associated effect on human health the Agency is moving toward a multi-pollutant approach. Ozone (O3) and nitrogen dioxide (NO2) are national ambient air quality standards (NAAQS) criteria pollutants that are major constituents of ambient air pollution. This study will address the Agency's goals by investigating the cardiopulmonary health effects of sequential exposure to O3 and NO2 in healthy adult human volunteers. The findings of this study will provide data that will inform risk assessment models for O3 and NO2 exposures. Additionally, the findings will provide insight into how the human health effects of multi-pollutant exposures differ from those of single pollutant exposures.

Read the detailed description

Despite improvements in air quality over the past several decades, over 100 million people in the U.S. still live in counties that do not meet the National Ambient Air Quality Standards (NAAQS) for one or more pollutants. During the course of daily living individuals are exposed to multiple pollutants from various sources of both natural and anthropogenic origin. It has become increasingly clear that air pollutant exposure is a risk factor for exacerbation and perhaps even progression of pulmonary and cardiovascular disease. The majority of controlled human exposure studies have examined individual pollutants; however, real-world exposures occur in the context of a complex mixture of pollutants. Different pollutants reach peak levels at different times during the day, which raises the concern that exposure to one pollutant may sensitize an individual so that their response to a subsequent exposure may be enhanced. Thus the sequence of exposure to these agents may affect their relative health effects and result in certain exposure scenarios being more deleterious than others.

To define multi-pollutant exposures that are relevant to real world scenarios we consulted experts in the EPA Office of Air and Radiation (OAR), who advised us to study the effects of sequential exposure to NO2 and O3, two ubiquitous NAAQS criteria pollutants. Ambient diurnal profiles of these two pollutants indicate that levels of NO2 often peak in the evening and morning hours, which are followed by peak ambient O3 concentrations during mid-day. Using this information we designed the study described here to determine whether sequential exposure to NO2 and O3, or O3 and NO2, will result in greater pulmonary and cardiovascular effects than exposure to either pollutant alone. Ozone is a major component of photochemical smog and is one of the most thoroughly studied gaseous pollutants. Controlled human exposure studies have been critical in demonstrating that it can cause airway inflammation, including increases in neutrophil infiltration into the lung and the production of pro-inflammatory mediators, and ultimately decrements in lung function. More recent studies have shown that ozone can also increase vascular inflammation, as well as alter autonomic nervous system control of heart rate. Nitrogen dioxide is an oxidant that is produced by natural and anthropogenic processes. The majority of man-made NO2 results from large-scale combustion-related processes, such as automobile emissions and the generation of electricity. Although traffic-related exposures account for the majority of NO2 emissions. Emissions from natural gas cooking appliances and kerosene-fueled space heaters with inadequate ventilation can serve as a significant source of human exposure to NO2 indoors. Previous studies have shown that NO2 concentrations can reach 600ppb in the area surrounding an operating gas stove, and peak levels may exceed 2000ppb. Controlled human exposure studies have indicated that exposure to NO2 alone (ranging from 110-2000ppb) results in little to no observable decrement in lung function; however, NO2 exposure has been associated with increases in airway hyper-responsiveness, susceptibility to pulmonary infection, and increased pulmonary inflammation. More recently, exposure to 500ppb NO2 has been associated with changes in cardiac electrophysiology. Recent epidemiological data indicate that exposure to NO2 from vehicle emissions were associated with both respiratory and cardiovascular-related mortality. Previous studies have shown that sequential exposure to NO2 and O3 (at concentrations similar to those proposed in this study) results in greater lung function decrements and increased non-specific airway responsiveness compared to O3 exposure preceded by clean air exposure in young women. Additional studies have demonstrated that sequential exposure to ozone, separated by 24 hours, resulted in greater lung function decrements, assessed as forced expiratory volume in the first second of exhalation (FEV1), following the second exposure than was observed after the first. Ozone exposure has also been shown to have a priming effect for subsequent exposure to sulfur dioxide (SO2) in adolescent asthmatics and allergen-induced responses of perennially allergic asthmatics. Additionally, ongoing research at the EPA Human Studies Facility has demonstrated that sequential exposure of humans to diesel exhaust and ozone can result in greater lung function decrement than exposure to either pollutant alone. Given the complex nature of pollutant exposure, we are interested in determining if exposure to one pollutant can sensitize a person so that subsequent exposure to a second pollutant would cause a more pronounced response than would be expected based on exposure to just the second pollutant alone. Thus, in this study we will examine two exposure scenarios involving sequential exposures of NO2 and O3. The first involves determining whether an initial exposure to NO2 will "prime" an individual to a subsequent O3 exposure. The second involves determining whether an initial exposure to O3, at a concentration that results in small cardiopulmonary changes that resolve within 24 hours, will augment a subsequent exposure to NO2. Generally speaking, exposure to NO2 alone is not associated with robust changes in metrics of cardiopulmonary function; however, we believe that it can modify, and be modified by, ozone exposure. Specifically, this study will test two general hypotheses. First, we hypothesize that pre-exposure to a relatively low concentration of NO2 will "sensitize" individuals to a subsequent O3 exposure and lead to greater changes in cardiopulmonary function compared to O3 exposure preceded by clean air exposure. Second, we hypothesize that pre-exposure to O3, at a concentration that has been previously associated with small changes in cardiopulmonary function, will prime individuals to have a greater response to NO2 compared to pre-exposure to clean air. The information obtained during the course of this study will enable the EPA to better evaluate the risks associated with sequential multi-pollutant exposure and potentially provide advice on activities to mitigate the effects.

Being tested
Ozone, Nitrogen dioxide
Keywords
Air pollution, Ozone, Nitrogen dioxide, Lung function, Cytokines
Medical subject headings
Respiratory Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OzoneOther

    Also called Trioxygen, CAS #10028-15-6

    Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.

  • Nitrogen dioxideOther

    Also called Nitrogen peroxide, CAS 310102-44-0

    Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.

Study groups in NCT02133586
Study groupRoleWhat they receive
Clean Air - O3Placebo comparatorDay #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise. Day #3: Follow-up (no exposure)
Receives: Other: Ozone
NO2-O3ExperimentalDay #1: Two-hour exposure to 500ppb nitrogen dioxide with intermittent exercise. Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise. Day #3: Follow-up (no exposure)
Receives: Other: Ozone; Other: Nitrogen dioxide
Clean Air - NO2Placebo comparatorDay #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise. Day #3: Follow-up (no exposure)
Receives: Other: Nitrogen dioxide
O3 - NO2ExperimentalDay #1: Two-hour exposure to 300ppb ozone with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise. Day #3: Follow-up (no exposure)
Receives: Other: Ozone; Other: Nitrogen dioxide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pulmonary Function

    Measurements are taken pre-exposure ("baseline" measurement), immediately post-exposure, and 24 hours post-exposure. Changes in forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) will be assessed as indicators of change in pulmonary function.

    Measured: Pre-exposure ("baseline"), immediately post-exposure, and 24 hours post-exposure

Secondary outcomes (1)
  1. Heart Rate Variability

    Measured: Pre-exposure ("baseline"), immediately post-exposure, and 24 hours post-exposure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionJan 2016
  4. Study completionJan 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
54 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02133586
Sponsor's protocol ID
ENDZONE
Acronym
ENDZONE
Status last verified
Aug 2020
First submitted
6 May 2014
Last updated
17 Aug 2020
Results posted
No
Data monitoring committee
No

Publications

  • Pulczinski JC, Rappold AG, Devlin RB, Diaz-Sanchez D, Bowers EC, Morgan DS, Case MW, McCullough SD. Sex modifies response to ozone and nitrogen dioxide: a controlled human exposure study. Inhal Toxicol. 2026 Jan;38(1):1-12. doi: 10.1080/08958378.2025.2574876. Epub 2025 Nov 17.

    PubMed 41246912

Questions about this trial

What is this clinical trial studying?

A study testing Ozone and Nitrogen dioxide in people with Respiratory Depression, run by Environmental Protection Agency (EPA) at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pulmonary Function (time frame: Pre-exposure ("baseline"), immediately post-exposure, and 24 hours post-exposure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02133586, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in